1 Executive Summary: India’s Pharmaceutical Sector 2008-2023
1.1 Prospects for India's Pharmaceutical Market
1.2 Aim, Scope and Format of the Report
2 Introduction to India's Pharmaceutical Sector
2.1 Historical Developments and Prospects for India's Pharmaceutical Sector
2.1.1 India's Early Years before 1970
2.1.2 Impetus for Increased Domestic Production 1970s
2.1.3 Development Phase 1980s and Growth Phase 1990s
2.1.4 Indian Pharmaceutical Industry Status in 2000s
2.3 Foreign Policy of India Related to Pharmaceutical Sector
2.4 India's GDP to Grow Significantly
2.5 India's Market Abroad
2.6 India's Purchasing Power Parity
2.7 Disease Epidemiology
2.7.1 Malaria
2.7.2 TB
2.7.3 HIV/AIDS
2.7.4 Pneumonia
2.7.5 Diarrhoea
2.7.6 Cancer
2.7.7 Cardiovascular Diseases
2.7.8 Diabetes
2.7.9 Asthma and Bronchitis
2.7.10 Neurological and Psychiatric Disorders and Addictions
2.8 Trend in Market for Individual Therapeutic Area
3 Analysis of the Indian Pharmaceutical Market
3.1 Pharmaceutical Market Analysis
3.2 Estimated Market Value for India's OTC Market
3.3 Estimated Market Value for India's Prescription Market
3.4 Estimated Market Volume for India's Generic Market
3.5 Branded Products Will Take Significant Market Share from 2008 to 2023
3.6 India's Major Selling Medicines
3.7 Sales Figure for Major Therapeutics Areas
3.8 Forecasts for Major Therapeutics Market: Anti-Infective
3.9 Forecasts for Major Therapeutics Market: Other Than Anti-Infective
3.10 Growth Rate in India's Therapeutic Market
4 Contract Manufacturing Businesses in India
4.1 Forecasts for Contract Manufacturing Services
4.2 Contract Manufacturing in India
4.2.1 Drivers for Contract Manufacturing for Outsourcing to India
4.3 Contract Manufacturing and Role of Indian Companies
4.3.1 Outsourcing for Generics
4.3.2 Sourcing Generics from Non-Competitors
4.3.3 Divi's Laboratories’ Business Model
4.3.4 Granules India for Production of Generic Prescription Medicines and OTCs
4.3.5 Matrix Contract Manufacturer for CNS Products
4.3.6 Neuland Focused on Anti-Bacterials
4.3.7 Natco Chose Chronic Diseases
4.4 Enforcing GMP Compliance for APIs in EU
4.5 Growth in Biotechnology Sector of India
4.5.1 Ranbaxy's Entry Into Biotechnology
5 Contract Research Businesses in India
5.1 Forecasts for Contract Research
5.2 Focus on Innovative R&D
5.3 CROs to Maintain High Quality
5.4 Drivers and Restrains for Outsourcing Clinical Research Services from India
5.5 Contract Research and Companies
5.5.1 R&D Investments by Foreign MNCs in India
5.5.2 Vimta is an Emerging Company
5.5.3 Suven is Emerging as a Contract R&D Focused
5.5.4 Wellquest is a CRO Compliant with International Regulatory Norms
5.6 Outsourcing Clinical Data Management
5.6.1 GlaxoSmithKline to Outsource Data Management
5.6.2 Clininvent is a CRO with Standardised Data Management Skills
5.7 Emerging Outsourcing Models
5.8 National Drug Authority to be Formed
5.9 Firsthand Interview for Expert Opinion on Clinical Research 1
5.9.1 Small and Medium Sized Companies Opt For CROs
5.9.2 Pros and Cons of Contract Research Services from India
5.9.3 India's Own Innovative Products
5.9.4 Differences between India and China for Undertaking Trials
5.10 Firsthand Interview for Expert Opinion on Clinical Research 2
5.10.1 Asian Nations with Proven Efficacy to Undertake Clinical Trials
5.11 Firsthand Interview for Expert Opinion on Clinical Research 3
5.11.1 Pros and Cons of Contract Research Services from India
6 India's Pharmaceutical Company Profile and Opportunities with Them
6.1 Suitable Business Models for Individual Pharmaceutical Companies in India
6.1.1 Merger and Acquisition (M&A) for Indian Companies
6.1.1.1 Dr Reddy Acquires Betapharm
6.1.2 Indian Pharmaceutical Companies Enter World Market
6.1.2.1 Zyday Cadila
6.1.2.2 Sun
6.1.2.3 Alkem
6.1.2.4 Wockhardt
6.1.2.5 Lupin
6.1.2.6 Ranbaxy
6.1.2.7 Cipla
6.1.3 Collaboration for Expansion and Improvement
6.1.4 Good Manufacturing Practice (GMP) Compliance
6.1.5 Foreign MNCs Maintain Significant Market Share in India
6.1.5.1 GlaxoSmithKline's Significant Market Share in India
6.1.5.2 Pfizer Emerged as the Most Significant Pharmaceutical Patent Applicant in India
7 SWOT Analysis for India's Pharmaceutical Market
7.1 The Existing Advantages of India's Pharmaceutical Sector
7.2 Vision for India's Pharmaceutical Sector
7.3 Goal of India's Pharmaceutical Sector
7.4 Visiongain Suggests Following Strategies for India’s Pharmaceutical Sector
7.5 Drivers and Restrain for India's Pharmaceutical Sector
7.6 India's Changing Demographic Profile
7.6.1 Public Healthcare System
7.6.2 Private Sector Contribution to Healthcare
7.6.3 Uneven Distribution of Healthcare
7.7 India's Pricing Pattern for Pharmaceutical Industry
7.7.1 Private Spending for Healthcare
7.7.2 Wholesale Distribution and Price Regulation
7.8 Firsthand Interview for Expert Opinion 1
7.8.1 Bureaucracy as Obstacles
7.8.2 Improving Access to Rural Areas
7.8.3 Therapeutic Areas to Get Increased Attention from 2008 to 2023
7.8.4 Drug Resistance for Antibiotics as Unmet Needs
7.9 Firsthand Interview for Expert Opinion 2
7.9.1 India's Key Strength
7.9.2 India's Edge Over China In Pharmaceutical Business
7.9.3 Need for Routine Inspection of Outsourcing Sites
7.9.4 Need for Creation of Economic Zone for Pharmaceutical Industry
7.9.5 Business Approach Needed for Rural Mass
7.9.6 India as an Emerging Market
7.9.7 Growth of India's Medical Tourism
7.9.8 Tropical Diseases Widespread in India
7.9.9 Vertical Integration Recommended for India's Companies
7.9.10 India's Emergence as a Major Pharmaceutical Market
8 Conclusions
8.1 India's Progress in Healthcare
8.2 Increases in Demand for Private Healthcare
8.3 Increases in Patient Demand for Service Provision
8.4 India's Progress in Pharmaceuticals and Outsourcing Services
8.5 Recommendations for India's Pharmaceutical Sector
8.6 Recommendations to Foreign Pharmaceutical Companies for India's Market
Tables
Table 1.1 Forecasts for India's Pharmaceutical Industry's Market, 2008, 2013, 2018 & 2023
Table 3.1 Pharmaceutical Sales ($bn) of Top 20 Nations, 2006
Table 3.2 India's Total Pharmaceutical Sales ($m), 2008-2014
Table 3.3 India's Total Pharmaceutical Sales ($m), 2015-2023
Table 3.4 Forecasts for India's Pharmaceutical Industry's Market, 2008, 2013, 2018 & 2023
Table 3.5 Forecasts for India's International OTC Market ($m), 2006- 2014
Table 3.6 Forecasts for India's International OTC Market ($m), 2015-2023
Table 3.7 Forecasts for India's Domestic OTC Market,($m), 2006-2014
Table 3.8 Forecasts for India's Domestic OTC Market ($m), 2015-2023
Table 3.9 Forecasts for India's Prescription Market ($m), 2006-2014
Table 3.10 Forecasts for India's Prescription Market ($m), 2015-2023
Table 3.11 Forecasts for Cephalosporins Sales ($m), 2006-2014
Table 3.12 Forecasts for Cephalosporins Sales( $m), 2015-2023
Table 3.13 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006-2014
Table 3.14 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015- 2023
Table 3.15 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014
Table 3.16 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023
Table 3.17 Forecasts for Macrolides Sales ($m), 2006-2014
Table 3.18 Forecasts for Macrolides Sales ($m), 2015-2023
Table 3.19 Forecasts for Anti-Malarial Sales ($m), 2006-2014
Table 3.20 Forecasts for Anti-Malarial Sales($m), 2015-2023
Table 3.21 Forecasts for Anti-TB Sales ($m), 2006-2014
Table 3.22 Forecasts for Anti-TB Sales ($m), 2015 -2023
Table 3.23 Forecasts for Anti-Diarrhoeal Sales($m), 2006-2014
Table 3.24 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023
Table 3.25 Forecasts for Amoebicides Sales($m), 2006-2014
Table 3.26 Forecasts for Amoebicides Sales ($m), 2015-2023
Table 3.27 Forecasts for NSAID Sales ($m), 2006-2014
Table 3.28 Forecasts for NSAID Sales ($m), 2015-2023
Table 3.29 Forecasts for H2 Receptor Blockers Sales($m), 2006-2014
Table 3.30 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023
Table 3.31 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014
Table 3.32 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023
Table 3.33 Forecasts for Anti-Tussives Sales ($m), 2006-2014
Table 3.34 Forecasts for Anti-Tussives Sales ($m), 2015-2023
Table 3.35 Forecasts for Haematinics, Iron and Combination Sales ($m), 2006-2014
Table 3.36 Forecasts for Haematinics, Iron and Combination Sales ($m), 2008-2023
Table 3.37 Forecasts for Anti-Epileptics Sales ($m), 2006-2014
Table 3.38 Forecasts for Anti-Epileptics Sales ($m), 2015-2023
Table 3.39 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014
Table 3.40 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023
Table 3.41 Forecasts for Expectorants Sales ($m), 2006-2014
Table 3.42 Forecasts for Expectorants Sales ($m), 2015-2023
Table 3.43 Forecasts for Topical Corticosteroids Sales ($m), 2006-2014
Table 3.44 Forecasts for Topical Corticosteroids Sales ($m), 2015-2023
Table 3.45 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2006-2014
Table 3.46 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2015-2023
Table 3.47 Forecasts for Antacid Sales ($m), 2006-2014
Table 3.48 Forecasts for Antacid Sales ($m), 2015 -2023
Table 3.49 Forecasts for Calcium Sales ($m), 2006-2014
Table 3.50 Forecasts for Calcium Sales ($m), 2015 -2023
Table 3.51 Forecasts for Vitamin B Complex Sales ($m), 2006-2014
Table 3.52 Forecasts for Vitamin B Complex Sales ($m), 2015-2023
Table 3.53 Forecasts for Anti-Histamine Sales ($m), 2006-2014
Table 3.54 Forecasts for Anti-Histamine Sales ($m), 2015-2023
Table 3.55 Forecasts for Anti-Depressant Sales ($m), 2006-2014
Table 3.56 Forecasts for Anti-Depressant Sales ($m), 2015-2023
Table 4.1 Forecasts for India's Contract Manufacturing Revenues ($m), 2006-2014
Table 4.2 Forecasts for India's Contract Manufacturing Revenues ($m), 2015-2023
Table 5.1 Forecasts for India's Contract Research Revenues ($m), 2006-2014
Table 5.2 Forecasts for India's Contract Research Revenues( $m), 2015-2023
Table 5.3 Dr Reddy's Pipeline Strength
Table 6.1 Fastest Growing Local Companies from Top 50 in India
Table 6.2 Leading Local Companies from Top 100 in India
Table 6.3 Leading Corporate Groups
Table 6.4 Merger and Acquisition Activities of Indian Companies, 2007
Table 6.5 International M&A of Indian Firms
Table 7.1 SWOT Analysis for India's Pharmaceutical Sector
Table 7.2 India's Demographic Profile, 2007
Figures
Figure 1.1 Forecasts for India's Pharmaceutical Industry's Market ($m), 2008, 2013,2018 & 2023
Figure 2.1 Developments and Prospects for India's Pharmaceutical Sector (Past,Present & Future)
Figure 2.2 India's Pharmaceutical Industry Culture and Attributes Figure 3.1 Countries Ranked by Pharmaceutical Market Share, 2006
Figure 3.2 Ratio of Domestic Pharmaceutical Market Share by Value with Export,2006
Figure 3.3 India's Total Pharmaceutical Sales ($m), 2006-2014
Figure 3.4 India's Total Pharmaceutical Sales ($m), 2015-2023
Figure 3.5 Forecasts for India's Pharmaceutical Industry's Market, 2008, 2013, 2018 & 2023
Figure 3.6 Forecasts for India's International OTC Market ($m), 2006-2014
Figure 3.7 Forecasts for India's International OTC Market ($m), 2015-2023
Figure 3.8 Forecasts for India's Domestic OTC Market ($m), 2006-2014
Figure 3.9 Forecasts for India's Domestic OTC Market ($m), 2015-2023
Figure 3.10 Ratio for Domestic and International OTC Market Share ($m), India, 2006
Figure 3.11 Forecasts for India's Prescription Market ($m), 2006-2014
Figure 3.12 Forecasts for India's Prescription Market ($m), 2015-2023
Figure 3.13 Proportion of India's Generic Market Share by Volume in Global Market,2008
Figure 3.14 Proportion of India's Generic Market Share by Volume in Global Market,2023
Figure 3.15 Ratio for Patent and Generic Market Share by Value, India, 2007
Figure 3.16 Ratio for Patent and Generic Market Share by Value, India, 2023
Figure 3.17 Major Anti-Infective Sales ($m), India, 2006
Figure 3.18 Major Selling Prescription Medicines Other Than Anti-Infective ($m),India, 2006
Figure 3.19 Major Selling OTC Medicines Other Than Anti-Infective ($m), India, 2006
Figure 3.20 Ratio of Anti-Infective to Other Medicines in the Market, India, 2008
Figure 3.21 Forecasts for Cephalosporins Sales ($m), 2006-2014
Figure 3.22 Forecasts for Cephalosporins Sales ($m), 2015-2023
Figure 3.23 Forecasts for Broad Spectrum Penicillin Sales ($m), 2006- 2014
Figure 3.24 Forecasts for Broad Spectrum Penicillin Sales ($m), 2015- 2023
Figure 3.25 Forecasts for Fluoro-quinolones Sales ($m), 2006-2014
Figure 3.26 Forecasts for Fluoro-quinolones Sales ($m), 2015-2023
Figure 3.27 Forecasts for Macrolides Sales ($m), 2006-2014
Figure 3.28 Forecasts for Macrolides Sales ($m), 2015-2023
Figure 3.29 Forecasts for Anti-Malarial Sales ($m), 2006-2014
Figure 3.30 Forecasts for Anti-Malarial Sales ($m), 2015-2023
Figure 3.31 Forecasts for Anti-TB Sales ($m), 2006-2014
Figure 3.32 Forecasts for Anti-TB Sales ($m), 2015 -2023
Figure 3.33 Forecasts for Anti-Diarrhoeal Sales ($m), 2006-2014
Figure 3.34 Forecasts for Anti-Diarrhoeal Sales ($m), 2015-2023
Figure 3.35 Forecasts for Amoebicides Sales ($m), 2006-2014
Figure 3.36 Forecasts for Amoebicides Sales ($m), 2015-2023
Figure 3.37 Forecasts for NSAIDs Sales ($m), 2006-2014
Figure 3.38 Forecasts for NSAIDs Sales ($m), 2015-2023
Figure 3.39 Forecasts for H2 Receptor Blockers Sales ($m), 2006-2014
Figure 3.40 Forecasts for H2 Receptor Blockers Sales ($m), 2015-2023
Figure 3.41 Forecasts for Oral Anti-Diabetics Sales ($m), 2006-2014
Figure 3.42 Forecasts for Oral Anti-Diabetics Sales ($m), 2015-2023
Figure 3.43 Forecasts for Anti-Tussives Sales ($m), 2006-2014
Figure 3.44 Forecasts for Anti-Tussives Sales ($m), 2015-2023
Figure 3.45 Forecasts for Haematinics, Iron and Combination Sales ($m), 2006-2014
Figure 3.46 Forecasts for Haematinics, Iron and Combination Sales ($m), 2008-2023
Figure 3.47 Forecasts for Anti-Epileptics Sales ($m), 2006-2014
Figure 3.48 Forecasts for Anti-Epileptics Sales ($m), 2015-2023
Figure 3.49 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2006-2014
Figure 3.50 Forecasts for Multi-Vitamins and Minerals Sales ($m), 2015-2023
Figure 3.51 Forecasts for Expectorants Sales ($m), 2006-2014
Figure 3.52 Forecasts for Expectorants Sales ($m), 2015-2023
Figure 3.53 Forecasts for Topical Corticosteroids Sales ($m), 2006- 2014
Figure 3.54 Forecasts for Topical Corticosteroids Sales ($m), 2015- 2023
Figure 3.55 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2006-2014
Figure 3.56 Forecasts for Angiotensin II Antagonist (Combination) Sales ($m), 2015-2023
Figure 3.57 Forecasts for Antacid Sales ($m), 2006-2014
Figure 3.58 Forecasts for Antacid Sales ($m), 2015 -2023
Figure 3.59 Forecasts for Calcium Sales ($m), 2006-2014
Figure 3.60 Forecasts for Calcium Sales ($m), 2015 -2023
Figure 3.61 Forecasts for Vitamin B Complex Sales ($m), 2006-2014
Figure 3.62 Forecasts for Vitamin B Complex Sales ($m), 2015-2023
Figure 3.63 Forecasts for Anti-Histamine Sales ($m), 2006-2014
Figure 3.64 Forecasts for Anti-Histamine Sales ($m), 2015-2023
Figure 3.65 Forecasts for Anti-Depressant Sales ($m), 2006-2014
Figure 3.66 Forecasts for Anti-Depressant Sales ($m), 2015-2023
Figure 3.67 Growth Rate According to Therapeutic Areas ($m), 2007
Figure 4.1 Forecasts for India's Contract Manufacturing Revenues ($m), 2008-2014
Figure 4.2 Forecasts for India's Contract Manufacturing Revenues ($m), 2015-2023
Figure 4.3 Path Up the Value Chain for Indian Companies
Figure 5.1 Forecasts for India's Contract Research Revenues ($m), 2008-2014
Figure 5.2 Forecasts for India's Contract Research Revenues ($m), 2015-2023